Newly Diagnosed: Where to Get Help10 min read

Understanding Your Lymphoma Diagnosis: Decoding Your Pathology Report and Hematologic Oncology Consultation

Hematologic-Oncology Lymphoma Newly-Diagnosed Pathology-Report Second-Opinion

A lymphoma pathology report contains the subtype, cell origin, grade, and molecular findings that shape every treatment decision that follows. This guide explains each section in plain English and tells you exactly what to do before your first hematologic oncology consultation.

HealthUnwired Team·05 Jul 2026

Understanding Your Lymphoma Diagnosis: Decoding Your Pathology Report and Hematologic Oncology Consultation

A lymphoma pathology report tells you three things: the subtype of lymphoma, the type of cells involved, and how quickly those cells are likely to grow. Each of these shapes the treatment options your hematologic oncologist will discuss with you. Understanding the report before your first appointment makes the conversation more productive and the decisions that follow clearer.

Why Your Pathology Report Is the Foundation of Your Care

When you receive a lymphoma diagnosis, a pathology report guides all your care. It is produced by a pathologist - a specialist who examines tissue removed during a biopsy. According to the National Cancer Institute, the pathology report provides the cancer diagnosis and guides all treatment planning.

For lymphoma, this report matters more than it does for many solid tumors. Non-Hodgkin lymphoma is not a single disease. The American Cancer Society describes it as a group of more than 50 cancers that begin in cells called lymphocytes - white blood cells that are part of the immune system. When scientists look at molecular differences, they have identified more than 100 subtypes. Your exact subtype, not just the word lymphoma, is what drives your treatment choices.

About 79,320 people in the United States are likely to receive a non-Hodgkin lymphoma diagnosis in 2026, with more than half over age 65 when diagnosed. If you are reading this after a recent biopsy result, you are far from alone - and understanding what your report says is the first step forward.

The Key Sections of a Lymphoma Pathology Report

Most lymphoma pathology reports follow a common structure. You do not need a medical background to understand the basics of each section.

Specimen Description

This section describes which body part provided the tissue sample and how doctors collected it. Common sources include a lymph node, bone marrow, or another area where lymphoma was suspected. The biopsy site matters because it affects what type of analysis the laboratory can run and whether you need additional samples.

The Diagnosis Line

This is the most important line in the report. It names your subtype of lymphoma. Examples you may see include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, classical Hodgkin lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Each subtype behaves differently, requiring different treatments. If you see unfamiliar terms, ask your oncologist to explain what your subtype means for your situation before any treatment begins.

Cell Origin: B-Cell, T-Cell, or NK-Cell

Lymphocytes come in several types. Memorial Sloan Kettering Cancer Center notes that B-cell lymphomas account for roughly 80 percent of non-Hodgkin lymphoma cases. T-cell and NK-cell (natural killer cell) lymphomas are less common but equally important to identify correctly - they often require different treatment strategies. Your pathology report should clearly state whether your lymphoma is B-cell, T-cell, or another origin. If it does not, ask your oncologist why and whether additional testing is planned.

Grade or Behavior: Indolent vs. Aggressive

Some lymphomas grow slowly over months or years. These are called indolent, or low-grade. Others grow quickly - these are called aggressive, or high-grade. Many patients assume slow-growing lymphomas are always better news, but that is not always true. Aggressive lymphomas sometimes respond more readily to treatment because rapidly dividing cells are more vulnerable to certain therapies. Your hematologic oncologist will explain what the grade means in your specific case.

Immunohistochemistry and Flow Cytometry

These are specialized lab tests that identify protein markers on the surface of cancer cells. They help confirm the subtype and may suggest targeted treatment options. Doctors typically use flow cytometry and immunohistochemical staining to confirm the lymphoma diagnosis. Your report may list markers such as CD20, CD10, BCL2, or BCL6. These identifiers help your oncologist understand the specific biology of your lymphoma and match it to appropriate treatments.

Molecular and Genetic Findings

Some reports include genetic test results. These may identify mutations or gene rearrangements - for example, MYC, BCL2, or BCL6 changes in diffuse large B-cell lymphoma. These findings can influence which treatments are most likely to work and whether you need additional molecular testing before finalizing any plan. If your report does not include a molecular section, ask whether your subtype needs molecular testing.

If any of these sections are missing or unclear, ask your oncologist to review the full report with you before you make any treatment decision. You have every right to a plain-language explanation of every part of your results.

How Lymphoma Is Staged: The Lugano Classification

Once doctors confirm your subtype, they use staging to describe how far the lymphoma has spread. Today doctors use the Lugano classification, which replaced the older Ann Arbor system. According to a paper in NIH PubMed Central, the Lugano classification is the international standard for staging both Hodgkin and non-Hodgkin lymphoma, and it now formally includes PET-CT imaging in the staging process.

The stages are numbered I through IV:

Stage I: The cancer is in one lymph node region or in one organ outside the lymph system.
Stage II: Cancer affects two or more lymph node groups on the same side of the diaphragm.
Stage III: Cancer affects lymph node groups on both sides of the diaphragm.
Stage IV: Lymphoma has spread widely to organs such as the bone marrow, liver, or lungs.

For Hodgkin lymphoma, the American Cancer Society notes that doctors add a letter A or B after the stage number. The letter A means you have no major systemic symptoms. The letter B means you have had fever, unexplained weight loss of more than 10 percent of your body weight, or drenching night sweats - called B symptoms. Some non-Hodgkin lymphoma subtypes use a similar designation for certain stages.

Stage alone does not tell the full story. A stage IV indolent lymphoma can have a very different outlook than a stage II aggressive lymphoma. Your hematologic oncologist will consider stage alongside subtype, molecular findings, and your overall health when discussing your options. For a broader introduction to how cancer staging works across cancer types, the HealthUnwired guide on understanding cancer staging and TNM classification provides a useful starting point.

What to Expect at Your Hematologic Oncology Consultation

A hematologic oncologist is a doctor who specializes in blood cancers - including all types of lymphoma, leukemia, and myeloma. Once your lymphoma subtype is confirmed through pathology, this specialist should lead your care.

At your first consultation, your hematologic oncologist will typically:

Review your pathology report in detail, often requesting the original tissue slides so their pathology team can review them again
Order or review imaging - usually a PET-CT scan, CT scan, or bone marrow biopsy - to confirm your stage
Discuss the treatment approaches relevant to your subtype and stage
Determine whether you need additional molecular testing before choosing a treatment

The first visit involves a large amount of information at once. Many patients find it overwhelming. Bringing a trusted person who can take notes helps. So does bringing a written list of questions. For a structured checklist of what to ask, see the HealthUnwired resource on questions to ask your oncologist at your first appointment.

Why a Second Opinion on Your Lymphoma Pathology Report Can Change Things

Getting a second opinion on a lymphoma diagnosis is a standard step in blood cancers - not a sign of doubt in your current doctor. It is a normal, healthy part of the process. It is especially valuable in lymphoma for several reasons.

First, many lymphoma subtypes look similar under a standard microscope. Expert hematopathologists - pathologists who focus on blood cancers - see far more cases each year than a general pathologist at a community hospital. Research in NIH PubMed Central found that specialized second-opinion review of PET-CT imaging in diffuse large B-cell lymphoma changed patient management decisions. That same principle applies to pathology slide review.

Second, the difference between two subtypes can completely change the treatment approach. A second opinion may confirm your original diagnosis - which itself builds confidence. Or it may refine the subtype classification, add needed molecular testing, or suggest a different treatment sequence.

Third, some molecular testing requires equipment that not all hospitals have. If your pathology report lacks genetic or molecular findings, a review at a specialist center can add those results before you begin treatment.

An online hematologic oncology consultation makes this step accessible from anywhere. A specialist can review your reports, slides, and scan files remotely - without traveling. For caregivers managing this research for a loved one, this is often the easiest first step. The HealthUnwired guide on the caregiver guide to lymphoma treatment options covers this scenario in detail.

How to Prepare Your Records Before Any Specialist Consultation

Whether your consultation is in person or online, gather the following documents before you arrive:

The full pathology report, including all appendices and molecular test results - not just the summary page
A digital copy or CD of all imaging studies (PET-CT, CT, or MRI scans)
Bone marrow biopsy report, if you had one
Recent blood count and chemistry panel results
A complete list of all current medications and supplements
A brief written note on your symptoms and when they first appeared

If your documents are in a language other than English and you are seeking care internationally, arrange for translation before the appointment. Most specialist platforms that handle oncology second opinions have secure document-upload processes and staff support to help with this step.

The waiting period between a lymphoma diagnosis and a first specialist consultation is often difficult emotionally. Many people feel anxious, struggle to sleep, and have trouble concentrating during these weeks. If you are having trouble sleeping or feel stressed, talk to your doctor about support options.

For a full walkthrough of how the online consultation process works - from uploading records to receiving a written specialist opinion - visit the HealthUnwired guide on your first online cancer consultation.

Your Next Concrete Step

Understanding your pathology report is not the end goal. It is the starting point for an informed conversation with a hematologic oncology specialist. If your current care team has not fully explained the subtype, cell origin, grade, and molecular findings in your report, you have a good reason to seek a second review before committing to a treatment plan.

You can book a video consultation with a verified hematologic oncologist on HealthUnwired, upload your reports securely, and receive a written specialist opinion without leaving home - typically within 48 hours.

When to Talk to Your Doctor

If you have been diagnosed with lymphoma and have not yet seen a hematologic oncologist, ask your doctor to refer you right away. If anything in your pathology report is unclear - including the subtype, grade, or molecular markers - ask for a plain-language explanation before agreeing to any treatment. If you have concerns about your proposed treatment plan, or if you have not had a complete staging workup including PET-CT imaging, a second opinion with a specialist is a reasonable and expected next step.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Hodgkin lymphoma is identified by the presence of a specific type of abnormal cell called the Reed-Sternberg cell, which a pathologist can see under a microscope. Non-Hodgkin lymphoma covers a much broader group - more than 50 subtypes - that start in B-cells, T-cells, or NK-cells but lack that specific cell marker. The two categories behave differently and require different treatment approaches, which is why accurate subtype identification through pathology is so important.

CD markers are proteins found on the surface of cancer cells. They are identified through tests called immunohistochemistry and flow cytometry. In lymphoma, these markers help the pathologist confirm the exact subtype and may indicate whether certain targeted treatments are worth considering. You do not need to interpret each marker yourself - your hematologic oncologist will explain which ones are relevant to your specific subtype and what they mean for your care.

The Lugano classification is the international staging system for both Hodgkin and non-Hodgkin lymphoma. It uses four stages (I through IV) to describe how widely the lymphoma has spread. It also incorporates PET-CT imaging, which helps assess whether lymphoma is metabolically active in specific areas of the body. Your hematologic oncologist uses your stage alongside your subtype and molecular findings to discuss your treatment options.

For most lymphoma diagnoses, a hematologic oncologist is the recommended specialist. These doctors focus specifically on blood cancers, including all types of lymphoma, leukemia, and myeloma. Because lymphoma has many subtypes that require different treatment strategies, the depth of specialization a hematologic oncologist brings can significantly affect your care decisions. A general oncologist may manage straightforward cases, but for any complex subtype or unusual molecular finding, specialist review is strongly advisable.

Yes. Online second opinions in lymphoma are available through specialist platforms that allow you to securely upload your pathology report, imaging files, and blood results for remote review by a hematologic oncologist. The specialist reviews your records and provides a written opinion, often within 48 hours. This is particularly useful for patients who are far from major cancer centers or who want an expert review before committing to a treatment plan.

Bring the full pathology report including all molecular results (not just the summary), a digital copy or CD of all imaging studies such as PET-CT, CT, or MRI scans, bone marrow biopsy results if available, recent blood count and chemistry results, a complete medication and supplement list, and a brief written summary of your symptoms and their timeline. Having all of these ready before your first appointment allows your hematologic oncologist to assess your case thoroughly from the start.